Endovia Health Sciences (EDVA) Capital Expenditures Growth (1y) (2015 - 2024)
Powered by 
Analysis
Endovia Health Sciences (EDVA) Capital Expenditures Growth (1y) (2015 - 2024) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.50 Bn | 133.65 Bn | 2.84 Bn | -22.99% |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn | 9.68% |
| 3 | Argenx Se | 65.05 Bn | 59.86 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.11 Bn | 51.98 Bn | 52.00 Mn | 1,133.33% |
| 5 | Revolution Medicines | 44.71 Bn | 44.71 Bn | - | - |
| 6 | BeOne Medicines | 40.40 Bn | 35.31 Bn | 1.53 Bn | -37.81% |
| 7 | Alnylam Pharmaceuticals | 35.36 Bn | 32.05 Bn | 992.69 Mn | 142.64% |
| 8 | Royalty Pharma | 28.16 Bn | 27.32 Bn | - | 22,433.30% |
| 9 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | -73.62% |
| 10 | Endovia Health Sciences | 801,166.21 | 558,464.21 | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | -26.54% |
| Dec 31, 2023 | -97.38% |
| Dec 31, 2020 | 3,017.74% |
| Sep 30, 2020 | -21.45% |
| Jun 30, 2020 | 206.41% |
| Mar 31, 2020 | -67.15% |
| Dec 31, 2019 | -91.51% |
| Sep 30, 2019 | -72.27% |
| Jun 30, 2019 | -122.51% |
| Mar 31, 2019 | -42.25% |
| Dec 31, 2018 | 205.12% |
| Sep 30, 2018 | 92.75% |
| Jun 30, 2018 | -41.87% |
| Mar 31, 2018 | -22.14% |
| Dec 31, 2017 | -33.84% |
| Sep 30, 2017 | -35.57% |
| Jun 30, 2017 | 179.11% |
| Mar 31, 2017 | -16.85% |
| Dec 31, 2016 | -9.97% |
| Sep 30, 2016 | 235.38% |